Abstract
Despite impressive preliminary efficacy of CAR-T cells in multiple myeloma (MM), NK cell engineering has emerged as a competitive and safer approach. NK-92 is a universal, cheap and fast cellular therapy previously used in clinical trials. Although modest responses with these cells have been reported in MM, their oncolytic potential can be enhanced by genetic modification. So far, two preclinical studies have been performed with CAR NK-92 against MM, targeting CD138 or CS1 (SLAMF7). However, there are still reasonable doubts about its clinical outcomes due to on-target off-tumor effect or fratricide, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
